P13K/AKT crosstalk with ER-signaling and cell survival
P13K/AKT crosstalk with ER-signaling and cell survival
批准号:
7330340
负责人:
Matthew E. Burow
金额:
$27.6万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-02-18 至 2010-12-31
关键词:
1-Phosphatidylinositol 3-KinaseAKT Signaling PathwayApoptosisApoptoticBiologicalBreast CarcinomaCell DeathCell SurvivalCellsCessation of lifeChemosensitizationComplexDataDevelopmentEstrogen AntagonistsEstrogen ReceptorsEstrogensGene ActivationGene ExpressionGene Expression RegulationGene MutationGenetic TranscriptionHormone ResponsiveHormonesLigandsLipidsMYBBP1A geneMalignant NeoplasmsMediatingNuclear Hormone ReceptorsNuclear ReceptorsPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphorylation SitePhosphotransferasesPhysiologicalProteinsProto-Oncogene Proteins c-aktReceptor ActivationReceptor Cross-TalkReceptor SignalingRegulationResearchResearch PersonnelResistanceRoleSelective Estrogen Receptor ModulatorsSignal PathwaySignal TransductionSite-Directed MutagenesisSystemTranscription CoactivatorWorkestrophilinpeptide hormoneprogramsreceptorreceptor function
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The primary long-term objective of this research is to understand the role of AKT-signaling cross-talk with the estrogen receptor (ER) in the control of cell survival and in the development of anti-estrogen resistance. We hypothesize that the AKT pathway functions to target and phosphorylate the p160 coactivator GRIP and ER proteins leading to regulation of CoA-recruitment, receptor-activation and gene expression. We further hypothesize that convergence of the AKT and estrogen signaling at the ER-CoA-transcriptional level is critical in the regulation of cell survival and influences selective estrogen receptor modulator (SERM) activity in hormone dependent cell systems such as breast carcinoma. The Specific Aims are proposed to 1) Determine the mechanisms of AKT-ER cross-talk by examining specific targeting, phosphorylation and activation of ER-AF2 and/or the p160 CoA GRIP by AKT and 2) Determine the physiological relevance of this cross-talk by examining effects of AKT-ER-CoA on the regulation of endogenous estrogen-responsive genes, alteration of SERM-activity and gene expression, and long-term cell survival. Specific Aim #1, To determine the role of AKT targeting and phosphorylation of ER-AF2 as a mechanism for cross-talk. We propose to determine if the ER-AF2 targeting occurs through direct phosphorylation by AKT and the role of specific phosphorylation sites in AKT-ER cross-talk. Specific Aim #2, To implicate AKT regulation of p160 coactivator-(GRIP) phosphorylation as a mechanism for activation of and recruitment to estrogen receptors. Studies will determine if AKT phosphorylates and activates GRIP though specific targeting of the GRIP-NRID (nuclear receptor interaction domain) or GRIP-AD2 (activation domain-2) as mechanisms for AKT regulation of GRIP in control of ER transcription. Specific Aim #3, to determine the requirement for GRIP phosphorylation/function in AKT-mediated regulation of ER-dependent cell survival, gene expression and SERM activity. In this aim, we will determine the role for specific AKT induced ER-CoA recruitment/activation in the regulation of cell survival gene expression (Bcl-2) and the influence of AKT-ER-CoA cross-talk on SERM activity. These studies will also determine if the mechanisms for AKT-phosphorylation of ER or GRIP from above are critical in the AKT-ER mediated regulation of cell survival. It is expected as a whole that this proposal will establish the mechanisms used by the investigator3K-AKT cascade to target the ER and the subsequent components of the ER transcription complex required for potentiation of activity by this pathway. This cross-talk and the mechanisms identified will be used to establish the biological relevancy of the pathway in terms of cell survival and altered SERM activity.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/mc.20532
发表时间:
2009-09
期刊:
MOLECULAR CARCINOGENESIS
影响因子:
4.6
作者:
[Payton-Stewart, Florastina, Schoene, Norberta W., Kim, Young S., Burow, Matthew E., Cleveland, Thomas E., Boue, Stephen M., Wang, Thomas T. Y.]
通讯作者:
Wang, Thomas T. Y.
DOI:
10.1371/journal.pone.0049067
发表时间:
2012
期刊:
PloS one
影响因子:
3.7
作者:
[Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME]
通讯作者:
Burow ME
DOI:
10.1289/ehp.1104296
发表时间:
2012-09
期刊:
Environmental health perspectives
影响因子:
10.4
作者:
[Bratton MR, Frigo DE, Segar HC, Nephew KP, McLachlan JA, Wiese TE, Burow ME]
通讯作者:
Burow ME
Systems genetics analyses predict a transcription role for P2P-R: molecular confirmation that P2P-R is a transcriptional co-repressor.
系统遗传学分析预测 P2P-R 的转录作用:分子证实 P2P-R 是转录共阻遏物。
DOI:
10.1186/1752-0509-4-14
发表时间:
2010-02-25
期刊:
BMC systems biology
影响因子:
--
作者:
[Peidis P, Giannakouros T, Burow ME, Williams RW, Scott RE]
通讯作者:
Scott RE
Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.
鞘氨醇激酶同种型的药理抑制会改变人类乳腺癌中的雌激素受体信号传导。
DOI:
10.1530/jme-10-0116
发表时间:
2011-06
期刊:
Journal of molecular endocrinology
影响因子:
3.5
作者:
[Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS]
通讯作者:
Beckman BS
共 9 条
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer
-
批准号:10503430
-
项目类别:
-
资助金额:$63.61万
-
财政年份:2022
-
负责人:Matthew E. Burow
-
依托单位:
Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer (Diversity Supplement - Belgodere)
-
批准号:10745843
-
项目类别:
-
资助金额:$11.02万
-
财政年份:2022
-
负责人:Matthew E. Burow
-
依托单位:
Characterization of an understudied kinase, NEK5, in acquisition of a mesenchymaland migratory cell phenotype
-
批准号:10047560
-
项目类别:
-
资助金额:$16.68万
-
财政年份:2020
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8463129
-
项目类别:
-
资助金额:$28.29万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8260576
-
项目类别:
-
资助金额:$30.1万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:7987895
-
项目类别:
-
资助金额:$32.24万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8082806
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
MEK5-Erk5 in breast cancer resistance
-
批准号:8660659
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2010
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:7163550
-
项目类别:
-
资助金额:$28.16万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6849312
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6993557
-
项目类别:
-
资助金额:$29.0万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:7344925
-
项目类别:
-
资助金额:$6.56万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6612489
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
P13K/AKT crosstalk with ER-signaling and cell survival
-
批准号:6706387
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2003
-
负责人:Matthew E. Burow
-
依托单位:
海外基金